{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:53:36Z","timestamp":1788544416355,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"DOI":"10.13039\/501100006447","name":"University of Zurich","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathologie"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Neuroendocrine (NE) cells in the prostate are part of the diffuse NE system and are found in both the normal prostate and acinar adenocarcinomas, occasionally exhibiting Paneth cell-like morphology.<\/jats:p>\n                  <jats:p>NE cells produce peptide hormones and biogenic amines that influence the differentiation and growth of the prostate glands through paracrine signaling; however, they do not show proliferative activity and lack androgen receptors (AR).<\/jats:p>\n                  <jats:p>Prostate tumors with NE differentiation are classified into five groups: (1)\u00a0acinar adenocarcinomas with partial NE differentiation, detectable only by immunohistochemistry, (2)\u00a0adenocarcinomas with Paneth cell-like differentiation, (3)\u00a0NE tumors\/carcinoids (NET), (4)\u00a0small cell NE carcinomas (SCNEC), and (5)\u00a0large cell NE carcinomas (LCNEC).<\/jats:p>\n                  <jats:p>The significance of partial and Paneth cell-like differentiation in adenocarcinomas remains under discussion and plays a\u00a0minor role in routine diagnostics. NETs are extremely rare and appear to behave similarly to NETs of the gastrointestinal tract. In contrast, SCNECs and LCNECs are aggressive tumors with important clinical relevance, as they have a\u00a0poor prognosis and require aggressive treatment.<\/jats:p>\n                  <jats:p>Therapy-associated neuroendocrine prostate carcinomas (t-NEPC) are recognized as a\u00a0distinct entity for the first time in the WHO classification (5th\u00a0edition, 2022). It arises through transdifferentiation via epigenetic changes following androgen deprivation and is characterized by AR loss and high proliferation, among other features. As with primary NE carcinomas, aggressive therapy is indicated. Therefore, a\u00a0follow-up biopsy is recommended for castration-resistant progressive prostate cancer to confirm this aggressive phenotype.<\/jats:p>","DOI":"10.1007\/s00292-025-01449-3","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T10:14:35Z","timestamp":1756116875000},"page":"26-34","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Neuroendocrine differentiation in prostate neoplasms","Neuroendokrine Differenzierung in Neoplasien der Prostata. Englische Version"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1901-7967","authenticated-orcid":false,"given":"Rainer","family":"Grobholz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"key":"1449_CR1","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/BF02655955","volume":"312","author":"K Pretl","year":"1944","unstructured":"Pretl\u00a0K (1944) Zur Frage der Endokrinie der menschlichen Vorsteherdr\u00fcse. Virch Arch\u00a0A 312:392\u2013404","journal-title":"Virch Arch A"},{"key":"1449_CR2","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0090-4295(98)00631-1","volume":"53","author":"G Aum\u00fcller","year":"1999","unstructured":"Aum\u00fcller\u00a0G, Leonhardt\u00a0M, Janssen\u00a0M et\u00a0al (1999) Neurogenic origin of human prostate endocrine cells. Urology 53:1041\u20131048","journal-title":"Urology"},{"issue":"2","key":"1449_CR3","doi-asserted-by":"publisher","first-page":"S141","DOI":"10.1093\/annonc\/12.suppl_2.S141","volume":"12","author":"H Bonkhoff","year":"2001","unstructured":"Bonkhoff\u00a0H (2001) Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status. Ann Oncol 12(2):S141\u2013S144","journal-title":"Ann Oncol"},{"key":"1449_CR4","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1002\/1097-0142(19950401)75:7+<1850::AID-CNCR2820751615>3.0.CO;2-4","volume":"75","author":"PA di Sant\u2019Agnese","year":"1995","unstructured":"di Sant\u2019Agnese\u00a0PA (1995) Neuroendocrine differentiation in prostatic carcinoma. Recent findings and new concepts. Cancer 75:1850\u20131859","journal-title":"Cancer"},{"key":"1449_CR5","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1097\/PAS.0000000000000208","volume":"38","author":"JI Epstein","year":"2014","unstructured":"Epstein\u00a0JI, Amin\u00a0MB, Beltran\u00a0H et\u00a0al (2014) Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol 38:756\u2013767","journal-title":"Am J Surg Pathol"},{"key":"1449_CR6","doi-asserted-by":"publisher","first-page":"5330","DOI":"10.1073\/pnas.91.12.5330","volume":"91","author":"YJ Bang","year":"1994","unstructured":"Bang\u00a0YJ, Pirnia\u00a0F, Fang\u00a0WG et\u00a0al (1994) Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc Natl Acad Sci USA 91:5330\u20135334","journal-title":"Proc Natl Acad Sci USA"},{"key":"1449_CR7","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1210\/me.2003-0031","volume":"17","author":"ME Wright","year":"2003","unstructured":"Wright\u00a0ME, Tsai\u00a0MJ, Aebersold\u00a0R (2003) Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. Mol Endocrinol 17:1726\u20131737","journal-title":"Mol Endocrinol"},{"key":"1449_CR8","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/pros.20338","volume":"66","author":"CG Sauer","year":"2006","unstructured":"Sauer\u00a0CG, Roemer\u00a0A, Grobholz\u00a0R (2006) Genetic analysis of neuroendocrine tumor cells in prostatic carcinoma. Prostate 66:227\u2013234","journal-title":"Prostate"},{"key":"1449_CR9","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1007\/s00292-005-0784-z","volume":"26","author":"CG Sauer","year":"2005","unstructured":"Sauer\u00a0CG, Trojan\u00a0L, Grobholz\u00a0R (2005) Bedeutung der neuroendokrinen Differenzierung im Prostatakarzinom. Pathologe 26:444\u2013452","journal-title":"Pathologe"},{"key":"1449_CR10","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.humpath.2005.02.019","volume":"36","author":"R Grobholz","year":"2005","unstructured":"Grobholz\u00a0R, Griebe\u00a0M, Sauer\u00a0CG et\u00a0al (2005) Influence of neuroendocrine tumor cells on proliferation in prostatic carcinoma. Hum Pathol 36:562\u2013570","journal-title":"Hum Pathol"},{"key":"1449_CR11","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1002\/pros.21392","volume":"71","author":"E Heinrich","year":"2011","unstructured":"Heinrich\u00a0E, Trojan\u00a0L, Friedrich\u00a0D et\u00a0al (2011) Neuroendocrine tumor cells in prostate cancer: Evaluation of the neurosecretory products serotonin, bombesin, and gastrin\u2014impact on angiogenesis and clinical follow-up. Prostate 71:1752\u20131758","journal-title":"Prostate"},{"key":"1449_CR12","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/00000478-199201000-00009","volume":"16","author":"MG Weaver","year":"1992","unstructured":"Weaver\u00a0MG, Karim\u00a0AFW, Srigley\u00a0J et\u00a0al (1992) Paneth cell-like change of the prostate gland. A\u00a0histological, immunohistochemical, and electron microscopic study. Am J Surg Pathol 16:62\u201368","journal-title":"Am J Surg Pathol"},{"key":"1449_CR13","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1016\/j.humpath.2014.08.004","volume":"45","author":"JS So","year":"2014","unstructured":"So\u00a0JS, Gordetsky\u00a0J, Epstein\u00a0JI (2014) Variant of prostatic adenocarcinoma with Paneth cell-like neuroendocrine differentiation readily misdiagnosed as Gleason pattern 5. Hum Pathol 45:2388\u20132393","journal-title":"Hum Pathol"},{"key":"1449_CR14","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1097\/00000478-200608000-00008","volume":"30","author":"EF Tamas","year":"2006","unstructured":"Tamas\u00a0EF, Epstein\u00a0JI (2006) Prognostic Significance of Paneth Cell-like Neuroendocrine Differentiation in Adenocarcinoma of the Prostate. Am J Surg Pathol 30:980\u2013985","journal-title":"Am J Surg Pathol"},{"key":"1449_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.humpath.2020.05.003","volume":"102","author":"DC Salles","year":"2020","unstructured":"Salles\u00a0DC, Mata\u00a0DA, Epstein\u00a0JI (2020) Significance of Paneth cell-like differentiation in prostatic adenocarcinoma: a\u00a0retrospective cohort study of 80\u00a0cases. Hum Pathol 102:7\u201312","journal-title":"Hum Pathol"},{"key":"1449_CR16","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S0022-5347(01)67648-1","volume":"153","author":"T Whelan","year":"1995","unstructured":"Whelan\u00a0T, Gatfield\u00a0CT, Robertson\u00a0S et\u00a0al (1995) Primary carcinoid of the prostate in conjunction with multiple endocrine neoplasia IIb in a\u00a0child. J\u00a0Urol 153:1080\u20131082","journal-title":"J Urol"},{"key":"1449_CR17","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/BF03347481","volume":"27","author":"B Goulet-Salmon","year":"2004","unstructured":"Goulet-Salmon\u00a0B, Berthe\u00a0E, Franc\u00a0S et\u00a0al (2004) Prostatic neuroendocrine tumor in multiple endocrine neoplasia Type 2B. J\u00a0Endocrinol Invest 27:570\u2013573","journal-title":"J Endocrinol Invest"},{"key":"1449_CR18","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.eururo.2003.08.014","volume":"45","author":"M Freschi","year":"2004","unstructured":"Freschi\u00a0M, Colombo\u00a0R, Naspro\u00a0R et\u00a0al (2004) Primary and pure neuroendocrine tumor of the prostate. Eur Urol 45:166\u2013169","journal-title":"Eur Urol"},{"key":"1449_CR19","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s11255-009-9660-8","volume":"42","author":"S Giordano","year":"2010","unstructured":"Giordano\u00a0S, Tolonen\u00a0T, Tolonen\u00a0T et\u00a0al (2010) A pure primary low-grade neuroendocrine carcinoma (carcinoid tumor) of the prostate. Int Urol Nephrol 42:683\u2013687","journal-title":"Int Urol Nephrol"},{"key":"1449_CR20","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1177\/10668969241228297","volume":"32","author":"M Alhamar","year":"2024","unstructured":"Alhamar\u00a0M, Sethi\u00a0S, Reuter\u00a0VE et\u00a0al (2024) Primary Well-Differentiated Neuroendocrine Tumor\/Carcinoid of the Prostate: Case Report and Review of Literature. Int J Surg Pathol 32:1374\u20131378","journal-title":"Int J Surg Pathol"},{"key":"1449_CR21","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00292-013-1855-1","volume":"35","author":"T Menter","year":"2014","unstructured":"Menter\u00a0T, Fischmann\u00a0A, Glatz\u00a0K (2014) PSAP expression in a\u00a0primary presacral neuroendocrine tumor. Potential for confusion with prostate cancer. Pathologe 35:277\u2013282","journal-title":"Pathologe"},{"key":"1449_CR22","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/BF00710831","volume":"410","author":"N Kimura","year":"1986","unstructured":"Kimura\u00a0N, Sasano\u00a0N (1986) Prostate-specific acid phosphatase in carcinoid tumors. Virchows Arch A Pathol Anat Histopathol 410:247\u2013251","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"key":"1449_CR23","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/modpathol.2017.44","volume":"30","author":"JW Park","year":"2017","unstructured":"Park\u00a0JW, Lee\u00a0JK, Witte\u00a0ON et\u00a0al (2017) FOXA2 is a\u00a0sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate. Mod Pathol 30:1262\u20131272","journal-title":"Mod Pathol"},{"key":"1449_CR24","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/1078-0432.CCR-13-1982","volume":"20","author":"HL Tan","year":"2014","unstructured":"Tan\u00a0HL, Sood\u00a0A, Rahimi\u00a0HA et\u00a0al (2014) Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin Cancer Res 20:890\u2013903","journal-title":"Clin Cancer Res"},{"key":"1449_CR25","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1111\/j.1464-410X.2011.10523.x","volume":"109","author":"S Deorah","year":"2012","unstructured":"Deorah\u00a0S, Rao\u00a0MB, Raman\u00a0R et\u00a0al (2012) Survival of patients with small cell carcinoma of the prostate during 1973\u20132003: a\u00a0population-based study. BJU Int 109:824\u2013830","journal-title":"BJU Int"},{"key":"1449_CR26","first-page":"4145","volume":"35","author":"S Alanee","year":"2015","unstructured":"Alanee\u00a0S, Moore\u00a0A, Nutt\u00a0M et\u00a0al (2015) Contemporary Incidence and Mortality Rates of Neuroendocrine Prostate Cancer. Anticancer Res 35:4145\u20134150","journal-title":"Anticancer Res"},{"key":"1449_CR27","doi-asserted-by":"publisher","first-page":"e793","DOI":"10.1016\/j.clgc.2017.04.006","volume":"15","author":"E Zaffuto","year":"2017","unstructured":"Zaffuto\u00a0E, Pompe\u00a0R, Zanaty\u00a0M et\u00a0al (2017) Contemporary Incidence and Cancer Control Outcomes of Primary Neuroendocrine Prostate Cancer: A\u00a0SEER Database Analysis. Clin Genitourin Cancer 15:e793\u2013e800","journal-title":"Clin Genitourin Cancer"},{"key":"1449_CR28","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/pros.20910","volume":"69","author":"DE Hansel","year":"2009","unstructured":"Hansel\u00a0DE, Nakayama\u00a0M, Luo\u00a0J et\u00a0al (2009) Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. Prostate 69:603\u2013609","journal-title":"Prostate"},{"key":"1449_CR29","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1038\/modpathol.2011.56","volume":"24","author":"SR Williamson","year":"2011","unstructured":"Williamson\u00a0SR, Zhang\u00a0S, Yao\u00a0JL et\u00a0al (2011) ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod Pathol 24:1120\u20131127","journal-title":"Mod Pathol"},{"key":"1449_CR30","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","volume":"22","author":"H Beltran","year":"2016","unstructured":"Beltran\u00a0H, Prandi\u00a0D, Mosquera\u00a0JM et\u00a0al (2016) Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med 22:298\u2013305","journal-title":"Nat Med"},{"key":"1449_CR31","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1002\/mc.22162","volume":"54","author":"L Wang","year":"2015","unstructured":"Wang\u00a0L, Williamson\u00a0SR, Zhang\u00a0S et\u00a0al (2015) Increased androgen receptor gene copy number is associated with TMPRSS2-ERG rearrangement in prostatic small cell carcinoma. Mol Carcinog 54:900\u2013907","journal-title":"Mol Carcinog"},{"key":"1449_CR32","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1002\/pros.23864","volume":"79","author":"AL Metzger","year":"2019","unstructured":"Metzger\u00a0AL, Abel\u00a0S, Wegner\u00a0RE et\u00a0al (2019) Patterns of care and outcomes in small cell carcinoma of the prostate: A\u00a0national cancer database analysis. Prostate 79:1452\u20131456","journal-title":"Prostate"},{"key":"1449_CR33","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aat5749","volume":"362","author":"JW Park","year":"2018","unstructured":"Park\u00a0JW, Lee\u00a0JK, Sheu\u00a0KM et\u00a0al (2018) Reprogramming normal human epithelial tissues to a\u00a0common, lethal neuroendocrine cancer lineage. Science 362:91\u201395","journal-title":"Science"},{"key":"1449_CR34","doi-asserted-by":"publisher","first-page":"175883592412696","DOI":"10.1177\/17588359241269676","volume":"16","author":"X Fei","year":"2024","unstructured":"Fei\u00a0X, Xue\u00a0JW, Wu\u00a0JZ et\u00a0al (2024) Promising therapy for neuroendocrine prostate cancer: current status and future directions. Ther Adv Med Oncol 16:17588359241269676","journal-title":"Ther Adv Med Oncol"},{"key":"1449_CR35","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.2013.54.3553","volume":"32","author":"HT Wang","year":"2014","unstructured":"Wang\u00a0HT, Yao\u00a0YH, Li\u00a0BG et\u00a0al (2014) Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis\u2014a systematic review and pooled analysis. J\u00a0Clin Oncol 32:3383\u20133390","journal-title":"J Clin Oncol"},{"key":"1449_CR36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s00292-005-0802-1","volume":"27","author":"R Grobholz","year":"2006","unstructured":"Grobholz\u00a0R, Riester\u00a0A, Sauer\u00a0CG et\u00a0al (2006) Regressive Ver\u00e4nderungen nach kurzzeitiger neoadjuvanter antiandrogener Therapie beim Prostatakarzinom. Wann ist das Grading nach Gleason noch sinnvoll? Pathologe 27:33\u201339","journal-title":"Pathologe"},{"key":"1449_CR37","first-page":"337","volume":"2","author":"G Acosta-Gonzalez","year":"2014","unstructured":"Acosta-Gonzalez\u00a0G, Qin\u00a0J, Wieczorek\u00a0R et\u00a0al (2014) De novo large cell neuroendocrine carcinoma of the prostate, case report and literature review. Am J Clin Exp Urol 2:337\u2013342","journal-title":"Am J Clin Exp Urol"},{"key":"1449_CR38","doi-asserted-by":"publisher","first-page":"1341794","DOI":"10.3389\/fonc.2024.1341794","volume":"14","author":"N Nguyen","year":"2024","unstructured":"Nguyen\u00a0N, Franz\u00a0RD, Mohammed\u00a0O et\u00a0al (2024) A systematic review of primary large cell neuroendocrine carcinoma of the prostate. Front Oncol 14:1341794","journal-title":"Front Oncol"},{"key":"1449_CR39","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1097\/00000478-200606000-00003","volume":"30","author":"AJ Evans","year":"2006","unstructured":"Evans\u00a0AJ, Humphrey\u00a0PA, Belani\u00a0J et\u00a0al (2006) Large cell neuroendocrine carcinoma of prostate: a\u00a0clinicopathologic summary of 7\u00a0cases of a\u00a0rare manifestation of advanced prostate cancer. Am J Surg Pathol 30:684\u2013693","journal-title":"Am J Surg Pathol"}],"container-title":["Die Pathologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-025-01449-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00292-025-01449-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-025-01449-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T13:27:47Z","timestamp":1765373267000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00292-025-01449-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":39,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1449"],"URL":"https:\/\/doi.org\/10.1007\/s00292-025-01449-3","relation":{},"ISSN":["2731-7188","2731-7196"],"issn-type":[{"value":"2731-7188","type":"print"},{"value":"2731-7196","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]},"assertion":[{"value":"6 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"R.\u00a0Grobholz declares that he has no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The supplement containing this article is not sponsored by industry.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}